CommercialCoverageMedium impact
08.01.71, Collagenase clostridium histolyticum (Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®)
Independence Blue Cross·Orthopedics, Plastic Surgery, Dermatology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
A commercial insurance policy for collagenase clostridium histolyticum medications (Xiaflex and Qwo) has been reissued and will take effect on May 28, 2025. This is a pharmacy policy update that may affect coverage or prior authorization requirements for these injectable medications used to treat Dupuytren's contracture and cellulite.
Action Required
By May 28, 2025: Review the updated policy at the provided URL to identify specific changes to coverage, prior authorization, or documentation requirements for Xiaflex and Qwo medications. Update billing protocols and prior authorization workflows as needed based on the new policy requirements.